Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2b data. The latest results ...
Results from the PATHFINDER 2 trial of Grail's blood test for multiple cancers have shown greater efficacy and a lower rate of false alarms than in an earlier trial of the technology. The Galleri ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback